Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic derivative of galantamine featuring a phthalimide-octyl side chain attached to the benzofurobenzazepine core. Galantamine derivatives are typically designed as acetylcholinesterase inhibitors and may also act on nicotinic acetylcholine receptors. These compounds are primarily investigated for their potential in treating neurodegenerative diseases such as Alzheimer's disease by enhancing cholinergic neurotransmission. The specific pharmacological profile and clinical development status of this particular derivative remain unclear from available sources[1][8].
- Other names
- GALANTHAMINE DERIVATIVEgalanthamine deriv. 4d(4aS,6R,8aS)-11-(8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl)-6-hydroxy-3-methoxy–5,6,9,10-tetrahydro–4aH-(1)benzofuro(3a , 3 , 2 - ef)(2)benzazepin–11–ium[ACD/IUPAC Name]Compound 711Compound711Compound-711
02
Targets
Acetylcholinesterase
Beyond the preview
Go deeper on (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (4aS,6R,8aS)-11-[8-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-yl)octyl]-6-hydroxy-3-methoxy-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-11-ium.